TUMOR ESCAPE MECHANISMS FROM IMMUNOSURVEILLANCE - INDUCTION OF UNRESPONSIVENESS IN A SPECIFIC MHC-RESTRICTED CD4+ HUMAN T-CELL CLONE BY THE AUTOLOGOUS MHC CLASS-II+ MELANOMA

被引:89
|
作者
BECKER, JC
BRABLETZ, T
CZERNY, C
TERMEER, C
BROCKER, EB
机构
[1] UNIV WURZBURG,INST DERMATOL,W-8700 WURZBURG,GERMANY
[2] UNIV WURZBURG,INST PATHOL,W-8700 WURZBURG,GERMANY
关键词
CD4+; IMMUNOSURVEILLANCE; MHC; TUMOR;
D O I
10.1093/intimm/5.12.1501
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The co-existence of tumor specific immunity with a progressing tumor is observed in a variety of experimental systems and remains one of the major paradoxes of tumor immunology. We now report that a human melanoma cell line (SMC) expressing MHC class II was able to induce clonal anergy in a specific, MHC-restricted CD4+ T cell clone (STC3). Clonal anergy is a mechanism of T lymphocyte tolerance induced by antigen receptor stimulation in the absence of co-stimulation. We observed that a CD4+ T cell clone and an autologous melanoma cell line form conjugates with each other that leads to an increase of [Ca++]i in the T cell clone; however, this interaction failed to induce IL-2 production or proliferation of the T cell clone. Furthermore, this interaction rendered this T cell clone unresponsive to subsequent stimulation. All these effects were MHC class II restricted. Therefore, the human melanoma cell line SMC was capable of delivering antigen-specific signals to the T cell clone, but did not deliver the co-stimulatory signals, e.g. a B7/CD28 interaction, necessary for full T cell activation. Transfection of the melanoma cells with an expression vector containing a B7 cDNA that resulted in subsequent expression of B7 on its cell surface rendered it into a fully competent antigen presenting cell, which is able to induce a nuclear factor binding to the IL-2 promoter in the specific T cell clone resulting in enhanced IL-2 transcription, synthesis, and T cell proliferation. These findings suggest that manipulation of co-stimulation may offer new strategies for future tumor immunotherapy.
引用
收藏
页码:1501 / 1508
页数:8
相关论文
共 11 条
  • [1] Isolation of human MHC class II-restricted T cell receptors from the autologous T-cell repertoire with potent anti-leukaemic reactivity
    Weigand, Luise U.
    Liang, Xiaoling
    Schmied, Sabine
    Mall, Sabine
    Klar, Richard
    Stoetzer, Oliver J.
    Salat, Christoph
    Goetze, Katharina
    Mautner, Josef
    Peschel, Christian
    Krackhardt, Angela M.
    IMMUNOLOGY, 2012, 137 (03) : 226 - 238
  • [2] Tumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display
    Tveita, Anders
    Fauskanger, Marte
    Bogen, Bjarne
    Haabeth, Ole Audun Werner
    ONCOTARGET, 2016, 7 (41) : 67175 - 67182
  • [3] CD4(+) T-LYMPHOCYTES INFILTRATING HUMAN BREAST-CANCER RECOGNIZE AUTOLOGOUS TUMOR IN AN MHC-CLASS-II RESTRICTED FASHION
    DADMARZ, R
    SGAGIAS, MK
    ROSENBERG, SA
    SCHWARTZENTRUBER, DJ
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1995, 40 (01) : 1 - 9
  • [4] Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR αβ gene transfer requires CD8α
    Willemsen, R
    Ronteltap, C
    Heuveling, M
    Debets, R
    Bolhuis, R
    GENE THERAPY, 2005, 12 (02) : 140 - 146
  • [5] Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR αβ gene transfer requires CD8α
    R Willemsen
    C Ronteltap
    M Heuveling
    R Debets
    R Bolhuis
    Gene Therapy, 2005, 12 : 140 - 146
  • [6] N-linked carbohydrates in tyrosinase are required for its recognition by human MHC class II-restricted CD4+ T cells
    Housseau, F
    Moorthy, A
    Langer, DA
    Robbins, PF
    Gonzales, MI
    Topalian, SL
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2001, 31 (09) : 2690 - 2701
  • [7] MHC class II and CD80 tumor cell–based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain
    Dan Ilkovitch
    Suzanne Ostrand-Rosenberg
    Cancer Immunology, Immunotherapy, 2004, 53 : 525 - 532
  • [8] Induction of CD4+ Th1 lymphocytes that recognize known and novel class 11 MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein
    Parkhurst, MR
    Riley, JP
    Robbins, PF
    Rosenberg, SA
    JOURNAL OF IMMUNOTHERAPY, 2004, 27 (02) : 79 - 91
  • [9] MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells
    Srivastava, Minu K.
    Bosch, Jacobus J.
    Wilson, Ashley L.
    Edelman, Martin J.
    Ostrand-Rosenberg, Suzanne
    INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (11) : 2612 - 2621
  • [10] Identification of Potential MHC Class-II-Restricted Epitopes Derived from Leishmania donovani Antigens by Reverse Vaccinology and Evaluation of Their CD4+T-cell Responsiveness against Visceral Leishmaniasis
    Dikhit, Manas Ranjan
    Kumar, Akhilesh
    Das, Sushmita
    Dehury, Budheswar
    Rout, Ajaya Kumar
    Jamal, Fauzia
    Sahoo, Ganesh Chandra
    Topno, Roshan Kamal
    Pandey, Krishna
    Das, V. N. R.
    Bimal, Sanjiva
    Das, Pradeep
    FRONTIERS IN IMMUNOLOGY, 2017, 8